Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers

Journal of the Neurological Sciences

Volumn 330, Issue 1-2, 2013, Pages 71-77

  Parisé, Hélène ^a   Laliberté, François ^a   Lefebvre, Patrick ^a   Duh, Mei Sheng ^b   Kim, Edward ^c   Agashivala, Neetu ^c   Abouzaid, Safiya ^c   Weinstock Guttman, Bianca ^d  

^a GROUPE D ANALYSE   (Canada)

^b ANALYSIS GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Caregivers; Direct cost; Indirect cost; Multiple sclerosis; Relapse frequency; Relapse severity; Relapses

Indexed keywords

ADULT; ARTICLE; CAREGIVER; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; SPOUSE;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; CAREGIVERS; COHORT STUDIES; COST OF ILLNESS; COSTS AND COST ANALYSIS; EMPLOYMENT; ENDPOINT DETERMINATION; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84878586522     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.04.007     Document Type: Article

References (31)

1. B.M. Keegan, and J.H. Noseworthy Multiple sclerosis Annu Rev Med 53 2002 285 302
2. U.S. Food and Drug Administration First monoclonal antibody treatment for multiple sclerosis approved. P04-107 Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2004/ucm108380.htm November 23 2004 [Accessed March 24, 2013]
3. National Multiple Sclerosis Society Who gets MS? Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/ who-gets-ms/index.aspx [Accessed March 24, 2013]
4. National Institute of Neurological Disorders and Stroke Multiple sclerosis: hope through research Available at: http://www.ninds.nih.gov/ disorders/multiple-sclerosis/detail-multiple-sclerosis.htm [Accessed March 24, 2013]
5. T. Vollmer The natural history of relapses in multiple sclerosis J Neurol Sci 256 2007 S5 S13
6. B.G. Weinshenker, B. Bass, G.P.A. Rice, J. Noseworthy, W. Carriere, and J. Baskerville The natural history of multiple sclerosis: a geographically based study 2: predictive value of the early clinical course Brain 112 1989 1419 1428
7. M.P. Sormani, D.K. Li, P. Bruzzi, B. Stubinski, P. Cornelisse, and S. Rocak Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis Neurology 77 2011 1684 1690
8. F.D. Lublin, M. Baier, and G. Cutter Effect of relapses on development of residual deficit in multiple sclerosis Neurology 61 2003 1528 1532
9. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine Relapses and progression of disability in multiple sclerosis N Engl J Med 343 2000 1430 1438
10. M. Kremenchutzky, G.P.A. Rice, J. Baskerville, D.M. Wingerchuk, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease Brain 129 2006 584 594
11. K. Whetten-Goldstein, F.A. Sloan, L.B. Goldstein, and E.D. Kulas A comprehensive assessment of the cost of multiple sclerosis in the United States Mult Scler 4 1998 419 425
12. G.C. Pope, C.J. Urato, E.D. Kulas, R. Kronick, and T. Gilmer Prevalence, expenditures, utilization, and payment for persons with MS in insured populations Neurology 58 2002 37 43
13. J.A. O'Brien, A.J. Ward, A.R. Patrick, and J. Caro Cost of managing an episode of relapse in multiple sclerosis in the United States BMC Health Serv Res 3 2003 17
14. G. Kobelt, J. Berg, D. Atherly, and O. Hadjimichael Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States Neurology 66 2006 1696 1702
15. J.D. Prescott, S. Factor, M. Pill, and G.W. Levi Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database J Manag Care Pharm 13 2007 44 52
16. M.B. Patwardhan, D.B. Matchar, G.P. Samsa, D.C. McCrory, R.G. Williams, and T.T. Li Cost of multiple sclerosis by level of disability: a review of literature Mult Scler 11 2005 232 239
17. K.J. Aronson Quality of life among persons with multiple sclerosis and their caregivers Neurology 48 1997 74 80
18. N. Figved, K.M. Myhr, J.P. Larsen, and D. Aarsland Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms J Neurol Neurosurg Psychiatry 78 2007 1097 1102
19. D.A. Ollendorf, E. Jilinskaia, and M. Oleen-Burkey Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population J Manag Care Pharm 8 2002 469 476
20. B.J. Chastek, M. Oleen-Burkey, and M.V. Lopez-Bresnahan Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims J Med Econ 13 2010 618 625
21. D. Yamamoto, and J.D. Campbell Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature Autoimmune Dis 2012 784364
22. G. Kobelt, P. Lindgren, A. Smala, A. Bitdch, M. Haupts, and H.W. Kolmel Costs and quality of life in multiple sclerosis. An observational study in Germany HEPAC 2 2001 60 68
23. G. Kobelt, P. Lindgren, and D. Parkin Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the United Kingdom EFI Research Reports, Stockholm, Sweden 2000
24. F. Henriksson, S. Fredrikson, T. Masterman, and B. Jonsson Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden Eur J Neurol 8 2001 27 35
25. D.T. Grima, G.W. Torrance, G. Francis, G. Rice, A.J. Rosner, and L. Lafortune Cost and health related quality of life consequences of multiple sclerosis Mult Scler 6 2000 91 98
26. C.V. Asche, M.E. Singer, M. Jhaveri, H. Chung, and A. Miller All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States J Manag Care Pharm 16 2010 703 712
27. H. Naci, R. Fleurence, J. Birt, and A. Duhig Economic burden of multiple sclerosis: a systematic review of the literature Pharmacoeconomics 28 2010 363 379
28. J. Ivanova, H.G. Birnbaum, S. Samuels, M. Davis, A.L. Phillips, and D. Meletiche The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US Pharmacoeconomics 27 2009 681 691
29. J. Halper The psychosocial effect of multiple sclerosis: the impact of relapses J Neurol Sci 256 2007 S34 S38
30. N. Murphy, C. Confavreux, J. Haas, N. König, E. Roullet, and M. Sailer Economic evaluation of multiple sclerosis in the UK, Germany, and France Pharmacoeconomics 13 1998 607 622
31. M.P. Amato, M.A. Battaglia, D. Caputo, G. Fattore, S. Gerzeli, and M. Pitaro The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy J Neurol 249 2002 152 163